MET and cancer: SMYD3 acts as a transcriptional activator of several downstream target genes involved in cancer-related pathways, such as cell death and proliferation (e.g., hTERT, Wnt10b) [14], [15], epithelial-mesenchymal transition (EMT) (e.g., SLUG, MMP2, Vim, c-Met) [4], [6], [18], [19], [20], as well as oncogenes (e.g., c-MYC, JAK/STAT, CTNNB1) [4] and cell cycle regulatory genes (e.g., CCNA2, CCND1, CCNE1, PCNA, CDK2) [4], [19], [21].